We are live on
!
Find out more
TCM
TCG Crossover Management Portfolio holdings
AUM
$3.5B
1-Year Est. Return
1,165.83%
This Fund
S&P 500
This Quarter
Est. Return
+354.84%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.03B
AUM Growth
+$1.16B
(+132%)
Cap. Flow
+$148M
Cap. Flow
% of AUM
7.28%
Top 10 Holdings %
Top 10 Hldgs %
65.94%
Holding
49
New
11
Increased
7
Reduced
5
Closed
8
Top Buys
| 1 |
ABVX
Abivax
ABVX
|
+$64.7M |
| 2 |
Liquidia Corp
LQDA
|
+$37.1M |
| 3 |
LBRX
LB Pharmaceuticals
LBRX
|
+$27.7M |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$27.6M |
| 5 |
Spyre Therapeutics
SYRE
|
+$17.9M |
Top Sells
| 1 |
CDTX
Cidara Therapeutics
CDTX
|
+$49M |
| 2 |
SLNO
Soleno Therapeutics
SLNO
|
+$15.6M |
| 3 |
Tango Therapeutics
TNGX
|
+$14.9M |
| 4 |
UPB
Upstream Bio Inc
UPB
|
+$10.6M |
| 5 |
THRD
Third Harmonic Bio
THRD
|
+$10.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ABVX
1
Abivax
ABVX
$12B
| $604M | 29.7% |
7,111,596
+1,055,000
| +17% | +$64.7M |
|
2
CG Oncology
CGON
$6.18B
| $148M | 7.27% |
3,670,206
| – | – |
|
3
Cogent Biosciences
COGT
$6.59B
| $97.6M | 4.8% |
6,798,162
-166,213
| -2% | -$1.97M |
|
4
Amylyx Pharmaceuticals
AMLX
$1.96B
| $84.9M | 4.17% |
6,243,812
+300,000
| +5% | +$2.82M |
|
|
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
| $76.1M | 3.74% |
3,136,480
+245,664
| +8% | +$4.37M |
|
|
6
Tango Therapeutics
TNGX
$4.73B
| $71.7M | 3.53% |
8,536,196
-2,199,804
| -20% | -$14.9M |
|
7
Ocular Therapeutix
OCUL
$2.06B
| $71.5M | 3.52% |
6,117,232
+798,084
| +15% | +$9.54M |
|
8
Dianthus Therapeutics
DNTH
$5.33B
| $66M | 3.25% |
1,676,624
+175,000
| +12% | +$4.47M |
|
|
TRML
9
DELISTED
Tourmaline Bio
TRML
| $62.7M | 3.09% |
1,311,783
-165,810
| -11% | -$4.6M |
|
10
Dyne Therapeutics
DYN
$3.79B
| $58.4M | 2.87% |
4,615,144
+848,484
| +23% | +$9.68M |
|
|
11
Agios Pharmaceuticals
AGIO
$2.33B
| $57.4M | 2.82% |
1,430,041
+733,038
| +105% | +$27.6M |
|
12
EyePoint Inc
EYPT
$1.14B
| $50.9M | 2.5% |
3,572,335
| – | – |
|
13
Fulcrum Therapeutics
FULC
$239M
| $48.3M | 2.38% |
5,250,000
| – | – |
|
14
Savara
SVRA
$1.16B
| $44.1M | 2.17% |
12,362,205
| – | – |
|
|
RAPT
15
DELISTED
RAPT Therapeutics
RAPT
| $42.2M | 2.08% |
1,636,275
| – | – |
|
16
Tyra Biosciences
TYRA
$1.89B
| $40.5M | 1.99% |
2,898,103
| – | – |
|
|
UPB
17
Upstream Bio Inc
UPB
$386M
| $39.8M | 1.96% |
2,117,103
-684,660
| -24% | -$10.6M |
|
|
18
Liquidia Corp
LQDA
$7.13B
| $38.9M | 1.91% |
+1,710,084
| New | +$37.1M |
|
19
Disc Medicine
IRON
$2.81B
| $30.7M | 1.51% |
465,257
| – | – |
|
20
Structure Therapeutics
GPCR
$3.4B
| $29.8M | 1.46% |
1,063,000
| – | – |
|
21
Xencor
XNCR
$1.08B
| $28.8M | 1.41% |
2,452,138
| – | – |
|
|
LBRX
22
LB Pharmaceuticals
LBRX
$910M
| $27.6M | 1.36% |
+1,745,016
| New | +$27.7M |
|
23
Revolution Medicines
RVMD
$38.7B
| $20.4M | 1% |
+436,473
| New | +$17.1M |
|
|
ATXS
24
DELISTED
Astria Therapeutics
ATXS
| $20.1M | 0.99% |
2,761,861
| – | – |
|
25
Korro Bio
KRRO
$180M
| $19.9M | 0.98% |
+416,301
| New | +$9.24M |
|
Similar funds
DILIC
IIM
ACM
BCP
AL
ACA
MSC
TH